Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial
Osteolysis causes recurrent pain and disability after total hip arthroplasty. We investigated the effect of the human monoclonal antibody denosumab on osteolytic lesion activity. No deaths or treatment-related serious adverse events occurred. This is the first clinical trial of an investigational drug for osteolytic that shows tissue-specific biological efficacy.
